BWA | JUL 2026 33 in Australia and underlines how much investor conviction has accumulated around the platform over time. Importantly, that capital was raised against a business that was already showing a more coherent product architecture than many medtech AI peers. In 2025, Harrison.ai unified its identity more clearly by bringing together its radiology and pathology businesses under a single brand, with earlier entities such as Annalise.ai and Franklin.ai tied more explicitly into one platform story. The company described that unification as a way to simplify how customers engage with it and to accelerate global growth across medical diagnostics. That matters because it suggests the business is moving beyond a collection of promising products and into something more integrated and scalable. The radiology side of the business appears to be the strongest proof point so far. Harrison.ai says its technology is used across 40+ NHS Trusts in the UK, by more than half of Australia’s radiologists, in every public emergency department in Hong Kong, and with customers in Europe and the United States. Those kinds of deployment claims are significant because they indicate the business is operating well beyond pilot-stage experi-
RkJQdWJsaXNoZXIy MTE4MTQ=